Identification of a Novel Immune-related Gene Signature for Prognosis and the Tumor Microenvironment in Patients with Uveal Melanoma Combining Single-cell and Bulk Sequencing Data

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Feb 16

PMID 36793711

Authors

Wanpeng Wang

Han Zhao

Sha Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Uveal melanoma (UVM) is the most invasive intraocular malignancy in adults with a poor prognosis. Growing evidence revealed that immune-related gene is related to tumorigenesis and prognosis. This study aimed to construct an immune-related prognostic signature for UVM and clarify the molecular and immune classification.

Methods: Based on The Cancer Genome Atlas (TCGA) database, single-sample gene set enrichment (ssGSEA) and hierarchical clustering analysis were performed to identify the immune infiltration pattern of UVM and classify patients into two immunity clusters. Then, we proposed univariate and multivariate Cox regression analysis to identify immune-related genes that related to overall survival (OS) and validated in the Gene Expression Omnibus (GEO) external validation cohort. The molecular and immune classification in the immune-related gene prognostic signature defined subgroups were analyzed.

Results: The immune-related gene prognostic signature was constructed based on S100A13, MMP9, and SEMA3B genes. The prognostic value of this risk model was validated in three bulk RNA sequencing datasets and one single-cell sequencing dataset. Patients in the low-risk group had better OS than those in the high-risk group. The receiver-operating characteristic (ROC) analysis revealed its strong predictive ability for UVM patients. Lower expression of immune checkpoint genes was presented in the low-risk group. Functional studies showed that S100A13 knockdown via siRNA inhibited UVM cell proliferation, migration, and invasion , with the increased expression of reactive oxygen species (ROS) related markers in UVM cell lines.

Discussion: The immune-related gene prognostic signature is an independent predictive factor for the survival of patients with UVM and provides new information about cancer immunotherapy in UVM.

Citing Articles

S100A13-driven interaction between pancreatic adenocarcinoma cells and cancer-associated fibroblasts promotes tumor progression through calcium signaling.

Xia L, Guo X, Lu D, Jiang Y, Liang X, Shen Y Cell Commun Signal. 2025; 23(1):51.

PMID: 39871271 PMC: 11773924. DOI: 10.1186/s12964-025-02049-7.

Single-cell analysis of matrisome-related genes in breast invasive carcinoma: new avenues for molecular subtyping and risk estimation.

Su L, Wang Z, Cai M, Wang Q, Wang M, Yang W Front Immunol. 2024; 15:1466762.

PMID: 39493752 PMC: 11530991. DOI: 10.3389/fimmu.2024.1466762.

Chen Y, Chen S, Wu Z, Cheng Q, Ji D Cancer Cell Int. 2024; 24(1):336.

PMID: 39385179 PMC: 11465649. DOI: 10.1186/s12935-024-03509-9.

Identification of feature genes and molecular mechanisms involved in cell communication in uveal melanoma through analysis of single‑cell sequencing data.

Lyu N, Wu J, Dai Y, Fan Y, Lyu Z, Gu J Oncol Lett. 2024; 28(5):503.

PMID: 39233824 PMC: 11369854. DOI: 10.3892/ol.2024.14636.

Single cell RNA-sequencing in uveal melanoma: advances in heterogeneity, tumor microenvironment and immunotherapy.

Tang S, Zhang Y, Huang S, Zhu T, Huang X Front Immunol. 2024; 15:1427348.

PMID: 38966635 PMC: 11222395. DOI: 10.3389/fimmu.2024.1427348.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Guo W, Liang X, Liu L, Guo Y, Shen S, Liang J . MiR-6872 host gene SEMA3B and its antisense lncRNA SEMA3B-AS1 function synergistically to suppress gastric cardia adenocarcinoma progression. Gastric Cancer. 2019; 22(4):705-722. DOI: 10.1007/s10120-019-00924-0. View

Aronow M, Topham A, Singh A . Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013). Ocul Oncol Pathol. 2018; 4(3):145-151. PMC: 5939716. DOI: 10.1159/000480640. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

Miao S, Qiu T, Zhao Y, Wang H, Sun X, Wang Y . Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Thorac Cancer. 2018; 9(9):1136-1144. PMC: 6119616. DOI: 10.1111/1759-7714.12797. View

Rowcroft A, Loveday B, Thomson B, Banting S, Knowles B . Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2019; 22(4):497-505. DOI: 10.1016/j.hpb.2019.11.002. View

Pan H, Lu L, Cui J, Yang Y, Wang Z, Fan X . Immunological analyses reveal an immune subtype of uveal melanoma with a poor prognosis. Aging (Albany NY). 2020; 12(2):1446-1464. PMC: 7053626. DOI: 10.18632/aging.102693. View

Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano R . Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. J Vasc Interv Radiol. 2018; 29(10):1369-1375. DOI: 10.1016/j.jvir.2018.04.030. View

Seiwert T, Burtness B, Mehra R, Weiss J, Berger R, Eder J . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17(7):956-965. DOI: 10.1016/S1470-2045(16)30066-3. View

10.

Souri Z, Wierenga A, Kroes W, van der Velden P, Verdijk R, Eikmans M . and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma. Cancers (Basel). 2021; 13(17). PMC: 8430821. DOI: 10.3390/cancers13174445. View

11.

Singh S, Gill A, Nlooto M, Karpoormath R . Prostate cancer biomarkers detection using nanoparticles based electrochemical biosensors. Biosens Bioelectron. 2019; 137:213-221. DOI: 10.1016/j.bios.2019.03.065. View

12.

Triebel F, JITSUKAWA S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E . LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990; 171(5):1393-405. PMC: 2187904. DOI: 10.1084/jem.171.5.1393. View

13.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

14.

Pierce A, Barron N, Linehan R, Ryan E, ODriscoll L, Daly C . Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur J Cancer. 2007; 44(1):151-9. DOI: 10.1016/j.ejca.2007.10.017. View

15.

Wessely A, Steeb T, Erdmann M, Heinzerling L, Vera J, Schlaak M . The Role of Immune Checkpoint Blockade in Uveal Melanoma. Int J Mol Sci. 2020; 21(3). PMC: 7037664. DOI: 10.3390/ijms21030879. View

16.

Gaur P, Bielenberg D, Samuel S, Bose D, Zhou Y, Gray M . Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res. 2009; 15(22):6763-70. DOI: 10.1158/1078-0432.CCR-09-1810. View

17.

Liu N, Qi M, Li K, Zeng W, Li J, Yin M . CD147 regulates melanoma metastasis via the NFAT1-MMP-9 pathway. Pigment Cell Melanoma Res. 2020; 33(5):731-743. DOI: 10.1111/pcmr.12886. View

18.

Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J . Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A. 2001; 98(24):13954-9. PMC: 61148. DOI: 10.1073/pnas.231490898. View

19.

Zhao H, Chen Y, Shen P, Gong L . Identification of Immune Cell Infiltration Landscape and Their Prognostic Significance in Uveal Melanoma. Front Cell Dev Biol. 2021; 9:713569. PMC: 8427429. DOI: 10.3389/fcell.2021.713569. View

20.

Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z . Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer. 2018; 119(10):1223-1232. PMC: 6251038. DOI: 10.1038/s41416-018-0296-2. View